Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile?

Neuro Oncol. 2021 Mar 25;23(3):347-349. doi: 10.1093/neuonc/noab006.

Authors

Andrew B Lassman¹, Timothy F Cloughesy²

Affiliations

¹ Division of Neuro-Oncology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, NewYork-Presbyterian Hospital, New York, New York.
² Neuro-Oncology Program and Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Brain Neoplasms* / drug therapy
Dacarbazine / therapeutic use
Humans
Oligodendroglioma* / drug therapy
Temozolomide / therapeutic use

Substances

Dacarbazine
Temozolomide

Grants and funding